Ani Pharmaceuticals Inc (ANIP)

$49.86

+0.59

(+1.21%)

Market is closed - opens 8 PM, 01 Dec 2023

Insights on Ani Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 10 quarters, 48.62M → 131.82M (in $), with an average increase of 10.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 8 quarters, -24.13M → 9.94M (in $), with an average increase of 105.7% per quarter

  • Vs HLN

    In the last 1 year, Haleon Plc Spon Ads has given 24.4% return, outperforming this stock by 7.0%

Performance

  • $49.25
    $50.38
    $49.86
    downward going graph

    1.22%

    Downside

    Day's Volatility :2.24%

    Upside

    1.03%

    downward going graph
  • $36.36
    $65.89
    $49.86
    downward going graph

    27.08%

    Downside

    52 Weeks Volatility :44.82%

    Upside

    24.33%

    downward going graph

Returns

PeriodAni Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-23.75%
-3.8%
0.0%
6 Months
9.6%
2.3%
0.0%
1 Year
17.44%
-6.7%
-6.2%
3 Years
66.66%
18.2%
-2.8%

Highlights

Market Capitalization
1.0B
Book Value
$22.57
Dividend Share
0.0
Dividend Yield
4.44%
Earnings Per Share (EPS)
0.54
PE Ratio
94.61
PEG Ratio
1.06
Wall Street Target Price
71.67
Profit Margin
2.98%
Operating Margin TTM
11.68%
Return On Assets TTM
3.11%
Return On Equity TTM
3.38%
Revenue TTM
449.4M
Revenue Per Share TTM
25.93
Quarterly Revenue Growth YOY
57.3%
Gross Profit TTM
177.6M
EBITDA
100.7M
Diluted Eps TTM
0.54
Quarterly Earnings Growth YOY
-0.89
EPS Estimate Current Year
4.43
EPS Estimate Next Year
4.26
EPS Estimate Current Quarter
0.84
EPS Estimate Next Quarter
0.87

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Ani Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 43.74%

Current $49.86
Target $71.67

Company Financials

FY17Y/Y Change
Revenue
176.8M
↑ 37.49%
Net Income
-1.1M
↓ 127.35%
Net Profit Margin
-0.61%
↓ 3.67%
FY18Y/Y Change
Revenue
201.6M
↑ 13.99%
Net Income
15.5M
↓ 1539.96%
Net Profit Margin
7.69%
↑ 8.3%
FY19Y/Y Change
Revenue
206.5M
↑ 2.47%
Net Income
6.1M
↓ 60.67%
Net Profit Margin
2.95%
↓ 4.74%
FY20Y/Y Change
Revenue
208.5M
↑ 0.93%
Net Income
-22.5M
↓ 470.0%
Net Profit Margin
-10.82%
↓ 13.77%
FY21Y/Y Change
Revenue
216.1M
↑ 3.67%
Net Income
-42.6M
↑ 88.94%
Net Profit Margin
-19.71%
↓ 8.89%
FY22Y/Y Change
Revenue
316.4M
↑ 46.38%
Net Income
-47.9M
↑ 12.42%
Net Profit Margin
-15.14%
↑ 4.57%
Q2 FY22Q/Q Change
Revenue
73.9M
↑ 14.54%
Net Income
-14.9M
↓ 25.87%
Net Profit Margin
-20.21%
↑ 11.01%
Q3 FY22Q/Q Change
Revenue
83.8M
↑ 13.49%
Net Income
-8.6M
↓ 42.37%
Net Profit Margin
-10.26%
↑ 9.95%
Q4 FY22Q/Q Change
Revenue
94.2M
↑ 12.42%
Net Income
-4.2M
↓ 50.66%
Net Profit Margin
-4.5%
↑ 5.76%
Q1 FY23Q/Q Change
Revenue
106.8M
↑ 13.32%
Net Income
1.4M
↓ 133.91%
Net Profit Margin
1.35%
↑ 5.85%
Q2 FY23Q/Q Change
Revenue
116.5M
↑ 9.14%
Net Income
6.2M
↑ 333.98%
Net Profit Margin
5.36%
↑ 4.01%
Q3 FY23Q/Q Change
Revenue
131.8M
↑ 13.11%
Net Income
9.9M
↑ 59.17%
Net Profit Margin
7.54%
↑ 2.18%
FY17Y/Y Change
Total Assets
412.1M
↑ 27.65%
Total Liabilities
237.4M
↑ 54.93%
FY18Y/Y Change
Total Assets
430.6M
↑ 4.48%
Total Liabilities
233.3M
↓ 1.7%
FY19Y/Y Change
Total Assets
456.8M
↑ 6.08%
Total Liabilities
244.0M
↑ 4.57%
FY20Y/Y Change
Total Assets
461.2M
↑ 0.96%
Total Liabilities
265.5M
↑ 8.81%
FY21Y/Y Change
Total Assets
771.6M
↑ 67.31%
Total Liabilities
412.9M
↑ 55.51%
FY22Y/Y Change
Total Assets
760.1M
↓ 1.49%
Total Liabilities
421.5M
↑ 2.1%
Q2 FY22Q/Q Change
Total Assets
751.3M
↑ 0.87%
Total Liabilities
414.4M
↑ 3.92%
Q3 FY22Q/Q Change
Total Assets
739.1M
↓ 1.63%
Total Liabilities
402.4M
↓ 2.88%
Q4 FY22Q/Q Change
Total Assets
760.1M
↑ 2.84%
Total Liabilities
421.5M
↑ 4.75%
Q1 FY23Q/Q Change
Total Assets
765.2M
↑ 0.68%
Total Liabilities
425.7M
↑ 1.0%
Q2 FY23Q/Q Change
Total Assets
859.3M
↑ 12.3%
Total Liabilities
424.9M
↓ 0.21%
Q3 FY23Q/Q Change
Total Assets
889.9M
↑ 3.56%
Total Liabilities
435.2M
↑ 2.43%
FY17Y/Y Change
Operating Cash Flow
39.4M
↑ 43.49%
Investing Cash Flow
-108.0M
↓ 29.9%
Financing Cash Flow
72.4M
↓ 10025.51%
FY18Y/Y Change
Operating Cash Flow
67.1M
↑ 70.16%
Investing Cash Flow
-27.4M
↓ 74.65%
Financing Cash Flow
-27.8M
↓ 138.44%
FY19Y/Y Change
Operating Cash Flow
45.6M
↓ 31.97%
Investing Cash Flow
-27.5M
↑ 0.62%
Financing Cash Flow
1.3M
↓ 104.49%
FY20Y/Y Change
Operating Cash Flow
15.3M
↓ 66.54%
Investing Cash Flow
-68.3M
↑ 148.0%
Financing Cash Flow
-1.4M
↓ 215.12%
FY21Y/Y Change
Operating Cash Flow
3.3M
↓ 78.24%
Investing Cash Flow
-105.5M
↑ 54.39%
Financing Cash Flow
194.6M
↓ 13622.93%
FY22Y/Y Change
Operating Cash Flow
-31.2M
↓ 1039.28%
Investing Cash Flow
-15.7M
↓ 85.08%
Financing Cash Flow
-5.1M
↓ 102.63%
Q2 FY22Q/Q Change
Operating Cash Flow
-11.5M
↓ 39.37%
Investing Cash Flow
-604.0K
↓ 72.27%
Financing Cash Flow
-1.4M
↓ 36.7%
Q3 FY22Q/Q Change
Operating Cash Flow
3.6M
↓ 131.55%
Investing Cash Flow
-9.8M
↑ 1524.83%
Financing Cash Flow
-911.0K
↓ 36.6%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.4M
↓ 221.45%
Investing Cash Flow
-3.1M
↓ 67.98%
Financing Cash Flow
-508.0K
↓ 44.24%
Q1 FY23Q/Q Change
Operating Cash Flow
21.4M
↓ 586.91%
Investing Cash Flow
-2.4M
↓ 25.11%
Financing Cash Flow
-4.5M
↑ 795.28%
Q2 FY23Q/Q Change
Operating Cash Flow
20.6M
↓ 3.72%
Investing Cash Flow
-6.8M
↑ 190.1%
Financing Cash Flow
80.2M
↓ 1862.31%

Technicals Summary

Sell

Neutral

Buy

Ani Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ani Pharmaceuticals Inc
Ani Pharmaceuticals Inc
-18.57%
9.6%
17.44%
66.66%
-11.38%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
5.98%
26.0%
-10.64%
19.59%
28.63%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
6.86%
6.2%
24.38%
15.65%
15.65%
Zoetis Inc.
Zoetis Inc.
11.97%
9.23%
14.05%
9.61%
87.27%
Viatris Inc.
Viatris Inc.
3.28%
-0.54%
-17.23%
-45.72%
-44.12%
Catalent, Inc.
Catalent, Inc.
-0.88%
8.65%
-21.07%
-58.84%
-0.2%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ani Pharmaceuticals Inc
Ani Pharmaceuticals Inc
94.61
94.61
1.06
4.43
0.03
0.03
0.04
22.57
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
59.48
59.48
1.87
2.29
0.11
0.09
0.01
20.39
Haleon Plc Spon Ads
Haleon Plc Spon Ads
25.21
25.21
NA
0.41
0.06
0.04
0.01
1.78
Zoetis Inc.
Zoetis Inc.
36.78
36.78
3.53
5.42
0.47
0.14
0.01
11.05
Viatris Inc.
Viatris Inc.
6.19
6.19
NA
2.95
0.09
0.03
0.05
17.39
Catalent, Inc.
Catalent, Inc.
211.02
NA
1.18
1.01
-0.22
0.0
0.0
21.58
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ani Pharmaceuticals Inc
Ani Pharmaceuticals Inc
Buy
$1.0B
-11.38%
94.61
2.98%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$11.1B
28.63%
59.48
10.71%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$39.6B
15.65%
25.21
11.05%
Zoetis Inc.
Zoetis Inc.
Buy
$82.7B
87.27%
36.78
27.24%
Viatris Inc.
Viatris Inc.
Hold
$11.2B
-44.12%
6.19
11.84%
Catalent, Inc.
Catalent, Inc.
Hold
$7.2B
-0.2%
211.02
-22.36%

Institutional Holdings

  • BlackRock Inc

    12.26%
  • Vanguard Group Inc

    5.55%
  • Rubric Capital Management LP

    4.15%
  • Dimensional Fund Advisors, Inc.

    2.74%
  • State Street Corporation

    2.72%
  • Global Alpha Capital Management Ltd.

    2.58%

Company Information

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.

Organization
Ani Pharmaceuticals Inc
Employees
600
CEO
Mr. Nikhil Lalwani
Industry
Health Technology

FAQs